Your search for evid returned 206 results

Rezzayo is expected to be available in the summer of 2023.

Pulmonary function tests may be beneficial every six months, may be of use in initiating noninvasive ventilation when indicated

An FDA panel has voted in favor of the safety and effectiveness of Paxlovid for COVID-19.

Higher genetically predicted plasma caffeine concentrations linked to lower risk for type 2 diabetes, with 43% of effect mediated by BMI.

Some clinically meaningful improvements seen compared with education or inactive control

Multifaceted intervention of assessment, education, and feedback increases likelihood of triple prescription fourfold over usual care

Previously, the treatment had been approved for patients 1 year of age and older.

Sudden unexplained infant death rates increased among non-Hispanic Black infants, but not overall

In general population studies, no change observed in general mental health or anxiety symptoms; minimal worsening seen in depression symptoms

Solanezumab is a humanized monoclonal antibody designed to increase clearance of soluble amyloid beta (Aβ) from the brain by binding to aggregated forms of Aβ.